For research use only. Not for therapeutic Use.
ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities[1].
ABC1183 (3 μM, 24 h) can block cell cycle progression and thus affect cell proliferation[1].
ABC1183 (oral gavage, 5 or 50 mg/kg) inhibits tumor proliferation through negative regulation of cell growth and pro-inflammatory signalling in male C57BL/6 mice[1].
| Catalog Number | I021196 |
| CAS Number | 1042735-18-1 |
| Synonyms | 4-[4-amino-2-(4-methylanilino)-1,3-thiazole-5-carbonyl]benzonitrile |
| Molecular Formula | C18H14N4OS |
| Purity | ≥95% |
| InChI | InChI=1S/C18H14N4OS/c1-11-2-8-14(9-3-11)21-18-22-17(20)16(24-18)15(23)13-6-4-12(10-19)5-7-13/h2-9H,20H2,1H3,(H,21,22) |
| InChIKey | CUDLEXBIVZPJBU-UHFFFAOYSA-N |
| SMILES | CC1=CC=C(C=C1)NC2=NC(=C(S2)C(=O)C3=CC=C(C=C3)C#N)N |
| Reference | [1]. Randy S Schrecengost，et al. In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183. J Pharmacol Exp Ther. 2018 Apr;365(1):107-116. |
